KeyBanc resumed coverage of Alcon with an Overweight rating and $87 price target. The analyst resumed coverage of the medical technology sector with a constructive view on the space. Industry fundamentals appear broadly positive relative to the past few years, the analyst tells investors in a research note. The firm would maintain or increase MedTech exposure into 2024, believing “several limiting factors are now in the rearview,” including previous COVID resurgences and subsequent staffing and supply chain challenges. Additionally, it expects a return to more consistent mid-single-digit average growth trends, supported by a healthy backdrop for hospital activity and elective procedural trends exiting 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALC:
- Alcon initiated with an Outperform at Bernstein
- Alcon price target raised to CHF 85 from CHF 80 at Deutsche Bank
- Alcon reports ‘positive’ topline results from Phase 3 COMET trials of AR-15512
- Lifecore expands relationship with Alcon through commercial arrangements
- 5 Top MedTech Stocks for 2024, According to Analysts from Baird